All News

PSS.scleroderma.arthritis.contractures

Best of 2024: BSR Guidelines for Systemic Sclerosis Management

d Jack Cush, MD

The British Society for Rheumatology has updated its 2015 guidelines for the management of patients with systemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.

Read Article
lupus,nephritis,GN

Best of 2024: Upside/Downside of Steroids in Lupus Nephritis

d Jack Cush, MD

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis demonstrates both the benefits and harms to early glucocorticoid regimens on lupus outcomes.

Read Article
tomatoes olive oil and whole grains

Best of 2024: Eating for Rheumatoid Arthritis

d Kathryn H. Dao, M.D.

The majority of practicing rheumatologists at RheumNow Live 2024 were unaware of the new ACR guidelines issued in 2022 regarding dietary and lifestyle recommendations for patients with Rheumatoid Arthritis. Dr. Monica Guma reviewed these guidelines during her lecture on the impact of diet on disease activity and therapeutic response.  

Read Article
vitamin-d-3091385_640.jpg

Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women

d Jack Cush, MD

A follow-up analysis of a randomized clinical trial found that the use of calcium and vitamin D supplements among postmenopausal women was associated with decreased risk for cancer mortality, but increased risk for cardiovascular disease mortality. The analysis is published in Annals of Internal Medicine.

Read Article
Best of 2024: BSR Guidelines for Systemic Sclerosis Management https://t.co/dnnRRsR5AU https://t.co/PnzPh6PzCE

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Eating for Rheumatoid Arthritis https://t.co/gtK3F6FdEB https://t.co/ILA6lSohh7

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women https://t.co/rFOW4OpZS7 https://t.co/A0EN8b9KYB

Links:

Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/dr3M3cnjRG https://t.co/1wewEuJRAl

Links:

Dr. John Cush RheumNow ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology. - Uveitis accounts for 10% of visual impairment globally - TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/fwhTxEpVG0 https://t.co/cKGdcDbz3d

Links:

Dr. John Cush RheumNow ( View Tweet)
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/PMVn5Pb1b3

Links:

Dr. John Cush RheumNow ( View Tweet)

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/zLxEOnWjpB https://t.co/I8jBcxO6rH

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency https://t.co/atoMR1YChT https://t.co/OeaF9QUGEz

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD. 30% of ILD has cough Chest CT 91% sensitive, 71% specific 5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/FKZyNU1s06 https://t.co/w5q0hOesEH
Dr. John Cush RheumNow ( View Tweet)
What is Osteoarthritis? A downloadable patient education page from JAMA. https://t.co/PfoimFgxRp https://t.co/WVQbofTzGC

Links:

Dr. John Cush RheumNow ( View Tweet)
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/XYeMl6ag9c https://t.co/ycM573lUGT

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Eli Lilly’s GLP-1 drug Zepbound [tirzepatide] to treat moderate to severe obstructive sleep apnea in adults with obesity in combination with increased physical activity and a reduced-calorie diet.” https://t.co/rYiM6JzmDX https://t.co/hO6CgH9pVs

Links:

Dr. John Cush RheumNow ( View Tweet)
12 minute JAMA Podcast on Dx & Rx of Lupus - featuring Caroline H. Siegel, MD, from HSS in NYC. https://t.co/4iHdQTFxxw https://t.co/zrNsartPlq

Links:

Dr. John Cush RheumNow ( View Tweet)
Cycling vs Switching after TNFi Failure in axSpA https://t.co/XG16tgcLbr https://t.co/ifgMtAB7LF

Links:

Dr. John Cush RheumNow ( View Tweet)
Three words that changed President Jimmy Carters life: Courage, Wisdom & Patience.

Dr. John Cush RheumNow ( View Tweet)

Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×